Month: March 2022

— Second Quarter Revenues of $1.2 Billion Increased 39%, Including Robust Organic Growth of 29% —— Reported Quarterly Diluted EPS of $2.69 and Adjusted EPS of $3.14, Up 42% Over Prior Year —— RV Retail Market Share Gains Accelerate; 14.3%, +100 bps Over Prior Year, Trailing Three Months Through January —— $72 million in Cash Returned to Shareholders Through Second Quarter Fiscal Year-To-Date — EDEN PRAIRIE, Minn., March 23, 2022 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor lifestyle product manufacturer, today reported financial results for the Company’s Fiscal 2022 second quarter. Second Quarter Fiscal 2022 ResultsRevenues for the Fiscal 2022 second quarter ended February 26, 2022, matched the record of $1.2 billion set in the first quarter...

Total revenues of $601.2 million and system-wide sales of $750.7 million 31 system-wide restaurants opened in 12 states Q4 2021 same-restaurant sales growth of 36.7% vs. Q4 2020 and 20.6% vs. Q4 2019 Q4 2021 same-restaurant traffic growth of 31.9% vs. Q4 2020 and 6.1% vs. Q4 2019BRADENTON, Fla., March 23, 2022 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG), (“First Watch” or the “Company”) the Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 26, 2021 (“Q4 2021”) and fiscal year ended December 26, 2021 (“2021”) compared to thirteen weeks ended December 27, 2020 (“Q4 2020”) and fiscal year ended December 27, 2020 (“2020”) and provided an outlook for the fiscal year ending December 25, 2022 (“2022”). “I am proud to share our...

2021 Revenue Increased 395% Year-Over-Year to $59.9 Million Fourth Quarter Revenue Increased 481% Year-Over-Year to $25.3 Million BILLERICA, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021. “During 2021, we drove significant year-over-year growth, launched our Total Turn-Key Solution for cannabis cultivators, created a significant backlog of future high-margin recurring revenues, drove tremendous pipeline velocity, implemented innovative technological advancements to our Vertical Farming Unit, and established ourselves as the leader in premium extraction solutions through a series...

First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDA Continue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that cover approximately 350 million lives by the end of 2022 Strong cash position with expected runway into 2025; $1.7 billion in cash and cash equivalents as of December 31, 2021 EQRx to host conference call and webcast today at 8:00 a.m. ETCAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the quarter and full year ended December 31, 2021 and provided an...

IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level, checkpoint combination therapy, and 2nd-generation approach IMA203CD8 Immatics entered a global licensing agreement with Bristol Myers Squibb to collaborate on clinical development of TCR Bispecific (TCER®) IMA401 targeting MAGEA4/A8; agreement includes $150million upfront payment, up to $770 million in milestone payments, tiered double-digit royalties and a co-promotion option in the U.S. TCER®IMA401 IND1approved by regulatory authorities in February 2022; initiation of patient treatment in the first half of 2022 TCER® IMA402 targeting PRAME demonstrated preclinical...

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023Completed patient enrollment in the 409 patient OVAL Phase 3 registration enabling trial investigating ofra-vec in patients with platinum-resistant ovarian cancerPreliminary data from ofra-vec Phase 2 trials in mCRC and rGBM expected in 2022VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in 2H 2022KOL event in NYC to discuss ofra-vec in ovarian cancer planned for April 11, 2022Conference Call and Webcast at 8:30 a.m. EDT TodayTEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical...

Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2021. “We are pleased to announce our full 2021 results and early 2022 trends. The trend in new ordering physicians as we enter the new year is extremely encouraging,” noted Valerie Palmieri, Aspira’s Executive Chair. “We are excited about the success of our collaboration...

Reports Sixth Consecutive Quarter of Double-Digit Revenue Growth Fourth Quarter 2021 Financial Highlights(All results compared to prior year period)Revenues were $212.5 million, an increase of 35.8%, compared to $156.5 million in the prior year period Net income was $15.4 million, compared to a net loss of $(5.9) million in the prior year period Adjusted EBITDA1 was $69.4 million, compared to $44.6 million in the prior year period Adjusted Net Income1 was $46.5 million, compared to $24.7 million in the prior year periodFull Year 2021 Financial Highlights(All results compared to prior year periods; Successor period is defined as the period from February 1, 2020 through December 31, 2020; Predecessor period is defined as the period from January 1, 2020 through January 31, 2020)Revenues were $712.3 million, compared to $472.4 million...